BriaCell Highlights Data For Antibody-Drug Conjugate Resistant And Central Nervous System Metastatic Breast Cancer At AACR 2024
Portfolio Pulse from Benzinga Newsdesk
BriaCell presented positive Phase 2 data for Bria-IMT™, showing promising results in ADC resistant and CNS metastatic breast cancer at AACR 2024. The data revealed a PFS of 4.2 months, double that of controls, and a clinical benefit rate of 56%. The findings also highlighted a 71% intracranial objective response rate in heavily pretreated patients, underscoring Bria-IMT™'s potential in advanced breast cancer treatment. Additionally, preclinical data for Bria-OTS+™ and Bria-PROS+™ will be presented, indicating ongoing research efforts.
April 09, 2024 | 12:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BriaCell's presentation of positive Phase 2 data for Bria-IMT™ at AACR 2024, showing efficacy in ADC resistant and CNS metastatic breast cancer, could positively impact BCTX's stock in the short term.
The positive data from the Phase 2 study of Bria-IMT™, particularly its efficacy in ADC resistant and CNS metastatic breast cancer, positions BriaCell and its stock (BCTX) favorably in the market. The significant potential in managing advanced breast cancer, highlighted by the clinical benefit rate and intracranial objective response rate, could lead to increased investor confidence and potential stock price appreciation in the short term. The anticipation of additional data on Bria-OTS+™ and Bria-PROS+™ further supports the company's ongoing research efforts and potential for future growth.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100